AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years

Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

AGC begins study to expand its Bio-CDMO capability in Japan

Piramal Pharma expands API capabilities at Digwal

Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies

AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain

The new facility is scheduled to start operation in the first half of 2024

Clarivate deals report highlights emerging trends in biopharma deal-making

RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape